Oncothyreon announces presentation of long-term Stimuvax data at World Conference on L...(Although Oncothyreon believes that any f...)

Date:8/3/2009

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

'/>"/>

SOURCE Oncothyreon Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon announces closing of $11.1 million registered direct financing
5. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Oncothyreon reports first quarter 2009 financial results
9. Oncothyreon regains compliance with NASDAQ listing requirements
10. Oncothyreon to present at Invest Northwest 2009
11. Oncothyreon reports full year and fourth quarter 2008 financial results